A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma

Area of Science:

• Dermatopathology
• Oncology
• Molecular Diagnostics

Background:

• Spindle cell melanoma (SCM) and desmoplastic melanoma (DM) present overlapping histopathological features, complicating accurate diagnosis.
• Clinical prognosis and therapeutic strategies differ between SCM and DM, highlighting the need for precise diagnostic tools.
• A direct comparison of diagnostic and therapeutic biomarkers for SCM and DM has been lacking.

Purpose of the Study:

• To conduct a comprehensive comparison of diagnostic and therapeutic biomarkers in SCM and DM.
• To identify key immunophenotypic differences to aid in distinguishing SCM from DM.
• To develop a diagnostic algorithm for improved differentiation of these melanoma subtypes.

Main Methods:

• Meta-review of existing literature on SCM and DM clinicopathological differences.
• Analysis of 38 archival melanoma cases (16 SCM, 18 DM, 4 mixed) using 50 routine diagnostic biomarkers.
• Assessment of gene amplification and expression status for drugable targets (e.g., HER2, EGFR, MET, MDM2, TP53, ALK, MYC, FLI-1, KIT) via fluorescent in situ hybridization (FISH).
• BRAF mutation analysis.

Main Results:

• S100 remains a reliable marker for melanoma diagnosis in both subtypes.
• Nine biomarkers showed distinct labeling patterns: SCM (laminin, p75, HMB45, c-kit, MelanA) and DM (collagen IV, trichrome, CD68, MDM2).
• A diagnostic algorithm utilizing MelanA and trichrome achieved 94% sensitivity in distinguishing DM from SCM.
• Protein overexpression of drugable targets was found in 92% of cases; BRAF mutations occurred in 16% overall (31% SCM, 5% DM).

Conclusions:

• This study provides the first comprehensive screening of diagnostic and therapeutic biomarkers for SCM and DM.
• The developed algorithm offers a reliable method for differentiating SCM from DM when histology is ambiguous.
• High rates of protein overexpression in drugable targets suggest potential therapeutic avenues for these melanoma subtypes.